Europe Readies For Big Changes In Device Postmarket Surveillance
This article was originally published in The Gray Sheet
Executive Summary
Europe may be on the cusp of a big drive toward a more clearly organized and more transparent postmarket vigilance system with new funds directed at the issue in the wake of device safety scandals. The European Commission recently launched the second phase of its joint action plan of near-term device and diagnostics reforms, pushing postmarket surveillance to the top of its agenda.
You may also be interested in...
New UK Market Surveillance Levy Could Cost Medtech Companies Millions Each Year
The exact size of the fee is not yet known, but the UK's Medicines and Healthcare products Regulatory Agency apparently says it will be necessary to maintain fully functioning market oversight.
In Case You Missed It: Top 10 Gray Sheet Stories In February
Our coverage of the highly anticipated release of the revised ISO 13485 international medical device quality systems standard attracted the most attention from Gray Sheet readers last month. Also popular: stories about FDA photography during facility inspections, European postmarket surveillance reforms, and policy updates focused on human factors.
In Case You Missed It: Top 10 "Gray Sheet" Stories In January
Our most popular content in January included exclusive analyses of 2015 FDA recalls, warning letters and approvals; business and legal news from Boston Scientific and Johnson & Johnson; a look at combination product reform efforts in the US; plans to improve postmarket surveillance in Europe; and more.